SG/PUT/MODERNA/90/0.1/20.09.24 | Market Closed - Euronext Paris 12:30:00 2024-06-10 pm EDT | ||
| 0.105 EUR | +23.53% |
|
| Current month | -16.00% | ||
| 1 month | -67.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 0.105 | +23.53% |
| 24-06-07 | 0.085 | -10.53% |
| 24-06-06 | 0.095 | 0.00% |
| 24-06-05 | 0.095 | -17.39% |
| 24-06-04 | 0.115 | -8.00% |
Real-time Euronext Paris
Last update June 10, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| U613S | |
| ISIN | DE000SU671U1 |
| Date issued | 2024-01-22 |
| Strike | 90 $ |
| Maturity | 2024-09-20 (102 Days) |
| Parity | 10 : 1 |
| Emission price | 1.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.545 € |
|---|---|
| Lowest since issue | 0.065 € |
| Spread | 0.01 € |
| Spread % | 9.09% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151
USD
Average target price
143.9
USD
Spread / Average Target
-4.68%
- Stock Market
- Warrants
- U613S Warrant
